» Articles » PMID: 35215887

The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Feb 26
PMID 35215887
Authors
Affiliations
Soon will be listed here.
Abstract

Omicron, the novel highly mutated SARS-CoV-2 Variant of Concern (VOC, Pango lineage B.1.1.529) was first collected in early November 2021 in South Africa. By the end of November 2021, it had spread and approached fixation in South Africa, and had been detected on all continents. We analyzed the exponential growth of Omicron over four-week periods in the two most populated of South Africa's provinces, Gauteng and KwaZulu-Natal, arriving at the doubling time estimates of, respectively, 3.3 days (95% CI: 3.2-3.4 days) and 2.7 days (95% CI: 2.3-3.3 days). Similar or even shorter doubling times were observed in other locations: Australia (3.0 days), New York State (2.5 days), UK (2.4 days), and Denmark (2.0 days). Log-linear regression suggests that the spread began in Gauteng around 11 October 2021; however, due to presumable stochasticity in the initial spread, this estimate can be inaccurate. Phylogenetics-based analysis indicates that the Omicron strain started to diverge between 6 October and 29 October 2021. We estimated that the weekly growth of the ratio of Omicron to Delta is in the range of 7.2-10.2, considerably higher than the growth of the ratio of Delta to Alpha (estimated to be in in the range of 2.5-4.2), and Alpha to pre-existing strains (estimated to be in the range of 1.8-2.7). High relative growth does not necessarily imply higher Omicron infectivity. A two-strain SEIR model suggests that the growth advantage of Omicron may stem from immune evasion, which permits this VOC to infect both recovered and fully vaccinated individuals. As we demonstrated within the model, immune evasion is more concerning than increased transmissibility, because it can facilitate larger epidemic outbreaks.

Citing Articles

Clinical characteristics and prediction model of re-positive nucleic acid tests among Omicron infections by machine learning: a real-world study of 35,488 cases.

Cao Y, Yao T, Li R, Tan L, Zhang Z, Qi J BMC Infect Dis. 2024; 24(1):1406.

PMID: 39695973 PMC: 11654198. DOI: 10.1186/s12879-024-10297-0.


COVID-19 mutations: An overview.

Sarkar M, Madabhavi I World J Methodol. 2024; 14(3):89761.

PMID: 39310238 PMC: 11230071. DOI: 10.5662/wjm.v14.i3.89761.


Incorporating social determinants of health into transmission modeling of COVID-19 vaccine in the US: a scoping review.

Duong K, Nguyen D, Kategeaw W, Liang X, Khaing W, Visnovsky L Lancet Reg Health Am. 2024; 35:100806.

PMID: 38948323 PMC: 11214325. DOI: 10.1016/j.lana.2024.100806.


The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.

Soni M, Migliori E, Fu J, Assal A, Chan H, Pan J Front Immunol. 2023; 14:1212203.

PMID: 37901229 PMC: 10612330. DOI: 10.3389/fimmu.2023.1212203.


Development and Validation of a Prediction Model of the Risk of Pneumonia in Patients with SARS-CoV-2 Infection.

Yi X, Fu D, Wang G, Wang L, Li J Can J Infect Dis Med Microbiol. 2023; 2023:6696048.

PMID: 37496884 PMC: 10368499. DOI: 10.1155/2023/6696048.


References
1.
Kochanczyk M, Grabowski F, Lipniacki T . Super-spreading events initiated the exponential growth phase of COVID-19 with ℛ higher than initially estimated. R Soc Open Sci. 2020; 7(9):200786. PMC: 7540800. DOI: 10.1098/rsos.200786. View

2.
Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

3.
Garcia-Beltran W, Denis K, Hoelzemer A, Lam E, Nitido A, Sheehan M . mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022; 185(3):457-466.e4. PMC: 8733787. DOI: 10.1016/j.cell.2021.12.033. View

4.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View

5.
Cromer D, Steain M, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2021; 3(1):e52-e61. PMC: 8592563. DOI: 10.1016/S2666-5247(21)00267-6. View